Single-dose rituximab in refractory lupus nephritis

Area of Science:

• Nephrology
• Rheumatology
• Immunology

Background:

• Rituximab is used off-label for lupus nephritis with reported benefits.
• The standard four-dose regimen is expensive and may cause side effects.
• Optimal dosing for rituximab in lupus nephritis remains undetermined.

Purpose of the Study:

• To assess the efficacy of a single rituximab dose in patients with refractory lupus nephritis.
• To evaluate clinical, biochemical, and serological responses to single-dose rituximab.
• To compare the outcomes of single-dose rituximab with established multi-dose regimens.

Main Methods:

• Prospective, open-label study of 14 patients with refractory lupus nephritis.
• Patients received one intravenous infusion of 375 mg/m(2) rituximab alongside standard care.
• Response was defined by complete or partial renal response criteria; B-cell depletion was monitored.

Main Results:

• Eleven out of 14 patients (79%) responded to single-dose rituximab.
• Complete renal response was observed in 2 patients, and partial response in 9.
• B-cell depletion lasted up to 8 months, with minimal reported side effects.

Conclusions:

• Single-dose rituximab demonstrates effectiveness in managing relapsed or refractory lupus nephritis.
• The longevity of B-cell depletion is comparable to multi-dose regimens.
• Single-dose rituximab presents a potentially safer and more cost-effective treatment option.